A combination of multiple biomarkers, such as plasma Gal3 plus other disease-specific markers (e.g., the level of plasma mHTT for HD), is needed to design reliable biomarker sets to monitor the disease progression of HD and other neurodegenerative diseases. This evidence concerns the gene LGALS3 and neurodegenerative disease.